Repligen Reports First Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Repligen (RGEN) PT Lowered to $940 at Truist Securities
April 29, 2025 4:03 PM EDTTruist Securities analyst Srikripa Devarakonda lowered the price target on Repligen (NASDAQ: RGEN) to $940.00 (from $975.00) while maintaining a Buy rating.
The analyst comments "While near-term investor focus remains on the Eylea tail, REGN continues to deliver growth on top/bottom line... More
Repligen (RGEN) PT Lowered to $914 at Jefferies
April 29, 2025 3:58 PM EDTJefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy rating.
The analyst comments "Bottom line: REGN entered Q1 w/ a fairly negative bias into the print given: 1) we were modeling Eylea to miss HERE given the issues w/ Good Days, its pt assistance... More
Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'
April 29, 2025 2:54 PM EDTJPMorgan analyst Rachel Vatnsdal lowered the price target on Repligen (NASDAQ: RGEN) to $190.00 (from $200.00) while maintaining a Overweight rating.
The analyst comments "Repligen (RGEN) reported a strong top-line and bottom-line 1Q beat while reiterating organic revenue growth for the year. Diving deeper, RGEN revenues of $169M came in above the Street of $164M, reflecting +11% organic growth y/y (vs. Street of +7.9% y/y), leading to adj. EPS of $0.39 (vs. Street of $0.34). RGEN raised its... More
